Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

other current assets 1,140,000 1,188,000

Total current assets 24,913,000 19,898,000

PROPERTY:

Leasehold improvements 669,000 646,000

Laboratory equipment 3,756,000 3,533,000

Furniture, fixtures and office equipment 913,000 873,000

5,338,000 5,052,000

Less accumulated depreciation and

amortization (3,537,000) (3,212,000)

Property, net 1,801,000 1,840,000

Other assets 1,527,000 1,259,000

TOTAL ASSETS $28,241,000 $22,997,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

JANUARY 31, APRIL 30,

2008 2007

Unaudited

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $2,387,000 $1,683,000

Accrued clinical trial site fees 244,000 228,000

Accrued legal and accounting fees 390,000 392,000

Accrued royalties and license fees 124,000 337,000

Accrued payroll and related costs 858,000 874,000

Notes payable, current portion - 379,000

Capital lease obligation, current portion 17,000 17,000

Deferred revenue 1,434,000 1,060,000

Other current liabilities 1,239,000 885,000

Total current liabilities 6,693,000 5,855,000

Notes pay
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... (PRWEB) May 20, 2015 The global ... of 22.3% during the forecast period of 2015 to ... increasingly being used in drug discovery and development process ... market growth. In addition to this,heavy investments by key ... applications are also propelling market growth. Browse 113 market ...
(Date:5/20/2015)...  Marc Tessier-Lavigne, president of The Rockefeller University, ... from The Marie-Josée and Henry R. Kravis Foundation ... will be the centerpiece of the University,s major ... Kravis Research Building, two stories high, will be ... city blocks following the shoreline of the East ...
(Date:5/20/2015)... SEATTLE , May 20, 2015  Resolution Bioscience ... of ctDx ALK TM , a blood-based liquid ... non-small cell lung carcinoma (NSCLC), the most common form ... the test to guide patients to personalized therapies and ... sample. The Department of Health, the CLIA ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 ... transporter assay services for Drug-Drug Interactions (DDI), Metabolism ... Pharma, a world leader in assessing impact of ... Systems Pharmacology supported by biosimulation, announced today that ... agreement allows both companies to expand their product ...
Breaking Biology Technology:Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... concludes no safety concerns for the use of chromium ... Application to market Chromax(R) chromium picolinate in Europe ... Nutrition 21, Inc. (Nasdaq: NXXI ), ... Iceland Health(R) and Diabetes Essentials brands, announced today that ...
... ... GIA announces the release of a comprehensive global report on ... significant deceleration in growth. Key factors slowing down growth in the ... going off patent, increasing proliferation of generics, falling drug costs, and ...
... in Quality by Design Initiative for Protein Therapeutics - ... Sciences, Inc. (Nasdaq: CALP ), a leading ... life sciences research, today launched the Staccato Protein Workstation ... therapeutics and biogenerics. , , With a ...
Cached Biology Technology:EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 2EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 3EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 4Global Prescription Drugs Market to Cross $897 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 2Global Prescription Drugs Market to Cross $897 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 3Global Prescription Drugs Market to Cross $897 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 4Caliper Life Sciences Introduces Staccato Protein Workstation for Automated Protein Sample Preparation & Analysis 2Caliper Life Sciences Introduces Staccato Protein Workstation for Automated Protein Sample Preparation & Analysis 3
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... , May 8, 2013 Many people are familiar with ... conditions, but few may be aware of the revolutionary contributions ... this month when Leonard Flom , M.D., ... (1926-2007), were inducted into the United States Patent and Trademark ...
... have discovered that fat cells in the knee secrete a ... for new gene therapies that could offer relief and mobility ... knee joints secretes a protein called pro-factor D which gives ... linked to arthritis," said Nirmal Banda, Ph.D., associate professor of ...
... faster leading to less expensive biofuels for ... together in an industrial setting, new research by ... A paper on the breakthrough, "Fungal Cellulases ... Cellulose Deconstruction," appears in the current edition of ...
Cached Biology News:Ophthalmologist Inventors of Human Identification Technology Inducted into National Inventors Hall of Fame 2Ophthalmologist Inventors of Human Identification Technology Inducted into National Inventors Hall of Fame 3Discovery shows fat triggers rheumatoid arthritis 2Combining strategies speeds the work of enzymes 2
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Biology Products: